(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The following reader question came in response to the column “Critical Guidance for Complying With Anesthesia Infection Control Rules,” which features insight from Clifford Gevirtz, MD, an ...
Zydus Lifesciences on Saturday announced the launch of Semaglutide Injection in India under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™, following patent expiry.
The approval expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care. Epinephrine is a non-selective alpha and beta adrenergic agonist.
Expands Amneal’s injectables portfolio with an essential medicine used in hospitals for emergency and perioperative care BRIDGEWATER, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results